• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Biohaven Pharmaceuticals

Quote




anonymous said:
Wasn’t she recently accused of promoting some potentially unhealthy diet supplements? Probably not the best person to hire but hey whatever it takes to sell a pill.
Click to expand...

I don't know about cuts, but always check our financials. This reminds me of the dot coms in the late 90's. Money flowing out like the Wolf of Wall Street, not much coming in.
 












A khardashian? What a joke! Your company is a total joke. Get ready for layoffs. You can’t get in to any offices and aren’t getting payer access either. How long can the company give it away? My guess is half of you are done soon. Worthless product..
 




anonymous said:
A khardashian? What a joke! Your company is a total joke. Get ready for layoffs. You can’t get in to any offices and aren’t getting payer access either. How long can the company give it away? My guess is half of you are done soon. Worthless product..
Click to expand...

Not sure what area of the country you’re referring to, but where I am our payer access is great and getting better. And in terms of getting into offices, I’m in the field most days as is most of my team. Access isn’t what it was pre-COVID but it’s not terrible either. And most importantly, it’s not a worthless product. I am on it myself and can say it’s a fantastic product. We’re getting paid well, company has been very good to us during the pandemic. Not perfect, but no company is. Is our sales force inflated? that’s a concern for sure. But, you sound jealous and uninformed.
 




Payer access is less than 50 percent nationwide. Other products are at least 10-15 percent better for patient access. The drug had marginal efficacy for a mild attack. If that’s you, great. But for most patients it’s not good enough. Many experience nausea. How do I know? Pharmacist here.
 




anonymous said:
Payer access is less than 50 percent nationwide. Other products are at least 10-15 percent better for patient access. The drug had marginal efficacy for a mild attack. If that’s you, great. But for most patients it’s not good enough. Many experience nausea. How do I know? Pharmacist here.
Click to expand...
wow you sound like a bitter competitor. NRX are doing great and TRX is climbing quickly..MOVE OVER.
 




















To all the negative losers on here. The world is shitty enough. Find something to be positive about or go vent to a therapist. This is a great company and if you want to waste your time coming on here to complain about how awful you have it then GTFO!!!! Goodbye.
 




Layoffs are not coming. Great things are happening in 2021 and Biohaven is having a wonderful launch year considering what we have been up against. Keep working hard! So much to look forward to.
 








Remember when they flew us all to Vegas and served buffet style food during a pandemic? Oh and then they told us we are “essential workers” and sent us out into the field without any real PPE besides a face shield? Luckily most district managers were pretty cool about it. Upper brass is out of touch and for any of you defending the company let’s be real. They don’t give a shit about any of us.
 




anonymous said:
Remember when they flew us all to Vegas and served buffet style food during a pandemic? Oh and then they told us we are “essential workers” and sent us out into the field without any real PPE besides a face shield? Luckily most district managers were pretty cool about it. Upper brass is out of touch and for any of you defending the company let’s be real. They don’t give a shit about any of us.
Click to expand...
Biohazard
 








I don’t appreciate the threats being slung at district reps right now alluding to firing reps if they can’t get face to face access with top accounts. I used to love this company.
 








Top Bottom
Back
Quote